TYK Medicines, Inc (2410.HK)

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including breast cancer and prostate cancer; TY-2136b, an oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor for the treatment of solid tumors; TY-2699a, a selective CDK7 inhibitor for the treatment of advanced/metastatic solid tumors; and TY-0540, a selective CDK2/4/6 inhibitor to treat advanced/metastatic solid tumors. In addition, it develops TY-1054, an oral yes associated protein-transcriptional enhanced associate domain inhibitor for cancer treatment; CDK4, preclinical-stage oral CDK4 inhibitor for cancer treatment; TY-3002, a small-molecule, orally administered glucagon like peptide-1 receptor agonist (GLP-1RA) intended for the treatment of type 2 diabetes mellitus (T2DM) and obesity; and EGFR/FAK (PROTAC) and PI3Ka to treat solid tumors; and GLP-1 for the treatment of T2DM and overweight or obesity. The company has a collaboration agreement with Qilu for development, manufacturing, and commercialization of TY-9591, a highly selective, irreversible EGFR-TKI self-developed by TYK Medicines to reduce the formation of toxic metabolites. The company was incorporated in 2017 and is headquartered in Huzhou, China.